Abstract | BACKGROUND: METHODS: Thirty patients were treated with neoadjuvant nab-paclitaxel (125 mg/m(2), days 1, 8, and 15) and carboplatin (area under the curve =2; days 1, 8, and 15) every 21 days for four cycles. Ninety matched patients received paclitaxel (80 mg/m(2), days 1, 8, and 15) and carboplatin every 21 days for four cycles. Weekly trastuzumab is recommended for overexpression of human epidermal receptor-2. The primary endpoint was pathologic complete response (defined as ypT0/is ypN0). Matching was conducted according to six variables: body mass index, clinical tumor stage, clinical lymph node status, estrogen receptor status, HER2 status, and trastuzumab receiving rate. RESULTS: CONCLUSION:
|
Authors | Liang Huang, Sheng Chen, Ling Yao, Guangyu Liu, Jiong Wu, Zhiming Shao |
Journal | International journal of nanomedicine
(Int J Nanomedicine)
Vol. 10
Pg. 1969-75
( 2015)
ISSN: 1178-2013 [Electronic] New Zealand |
PMID | 25792830
(Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 130-nm albumin-bound paclitaxel
- Albumins
- Antineoplastic Agents
- Carboplatin
- Trastuzumab
- Paclitaxel
|
Topics |
- Adolescent
- Adult
- Aged
- Albumins
(therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- Breast Neoplasms
(drug therapy)
- Carboplatin
(therapeutic use)
- Female
- Humans
- Middle Aged
- Paclitaxel
(therapeutic use)
- Trastuzumab
(therapeutic use)
- Young Adult
|